Boehringer gets most US antitrust claims over drug-device combination treatments dismissed
MLex Summary: Boehringer Ingelheim Pharmaceuticals was granted the dismissal of US claims accusing it of engaging in sham patent litigation to thwart generic competition in multiple markets, including those for Combivent...To view the full article, register now.
Already a subscriber? Click here to view full article